Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cantargia in connection with the sale of immunology program CAN10
Mandate

Vinge advises Cantargia in connection with the sale of immunology program CAN10

July 21, 2025

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.

Upon closing of the transaction, Cantargia will receive a USD 33 million upfront cash payment, and Cantargia is eligible to up to an additional USD 580 million in milestone payments. Cantargia is also entitled to up to double digits tiered earn-out payments from global product sales.

The Vinge team includes Sofie Nordgren, Christian Lindhé, Martin Madsen Svanberg and Carolina Lundh.

Related

Vinge advises the financing banks in connection with Verdane and Telenor’s partnership in Telenor Connexion

 Vinge has advised a syndicate of Nordic and Northern European banks connection with the financing of Verdane and Telenor’s new partnership relating to Telenor Connexion. Under the partnership, Verdane and Telenor will jointly invest in Telenor Connexion, a leading provider of IoT solutions. The transaction was completed on 10 September 2026 and values Telenor Connexion at SEK 7.5 billion.
September 23, 2026

Vinge advises Accru Partners on its EUR 550 million senior secured bond issuance

 Vinge advises Accru Partners, backed by Axcel, in connection with Accru Partners’ inaugural EUR 550 million issuance of senior secured bonds.
September 23, 2026

Vinge advises Sveafastigheter on EUR 350 million bond issuance

 Vinge has advised Sveafastigheter AB (publ) on the issuance of EUR 350 million in senior unsecured bonds under its existing EUR 2 billion EMTN programme.
September 23, 2026